X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 3, 2021
X4 Pharmaceuticals (Nasdaq: XFOR) will report its financial results for Q2 ended June 30, 2021, on August 3, 2021. The company will also provide updates on recent business highlights during a conference call scheduled at 8:30 a.m. ET on the same day. Investors can access the call by dialing (866) 721-7655 or internationally at (409) 216-0009, using conference ID 2236266. X4 is developing mavorixafor, a novel therapy targeting the CXCR4 pathway, currently being evaluated in multiple clinical trials for rare diseases and cancers.
- X4 is advancing its lead candidate mavorixafor in a global Phase 3 trial for WHIM syndrome.
- Positive updates regarding ongoing clinical trials could enhance investor confidence.
- Limited treatment options indicate potential challenges in gaining market traction.
- Dependence on the success of mavorixafor presents risks for future revenue.
BOSTON, July 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2021, and provide an update on recent business highlights, on August 3, 2021.
The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 2236266. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay of the conference call will be available on the website.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.
Investors and Media:
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com
FAQ
What date will X4 Pharmaceuticals report its Q2 2021 financial results?
How can I access the conference call for X4 Pharmaceuticals' Q2 results?
What is the focus of X4 Pharmaceuticals' clinical development?
What is mavorixafor and what is its significance?
